Advice
following an abbreviated submission:
glycopyrronium (Sialanar®) is accepted for use within NHS Scotland.
Indication under review: symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
The availability of glycopyrronium (Sialanar®) provides a licensed alternative to an existing generic preparation used outwith the terms of its marketing authorisation, at a small additional cost.
Download detailed advice69KB (PDF)
Medicine details
- Medicine name:
- glycopyrronium bromide (Sialanar)
- SMC ID:
- 1254/17
- Indication:
- For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
- Pharmaceutical company
- Proveca Limited
- BNF chapter
- Anaesthesia
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 July 2017